Bionano Genomics (BNGO) announced that the American Society of Hematology, ASH, Annual Meeting and Exposition 2024 will feature a broad range of content covering OGM’s utility for research in areas including myeloid cancer, hematological malignancy, leukemia and blood disorders. Thirteen posters featuring results from OGM applications in cytogenomic research will be presented at the conference. Three of the 13 posters were presented in sessions dedicated towards AML and ALL clinical research applications.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNGO:
- Ladenburg downgrades Bionano Genomics on restructuring uncertainty
- Bionano Genomics downgraded to Neutral from Buy at Ladenburg
- Bionano Genomics Sees Growth in OGM Adoption
- Bionano Genomics reports Q3 revenue $6.1M, consensus $7.85M.
- Options Volatility and Implied Earnings Moves Today, November 13, 2024